Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...

Bain Capital’s Life Sciences team led the funding round, with contributions from new investor Wellington Management.

Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review ...

The study, published in The Lancet, a team from the Moorfields Eye Hospital and University College London Institute of ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...

None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.

Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine.

Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine. In ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

The layoffs at the gene therapy company are part of restructuring of Spark Therapeutics by its owner, Roche Group.